Portfolio auf einen Blick
Wertschriften per 31. Dezember 2022
|
Gesellschaft |
|
Anzahl Wert- schriften |
|
Verände- rung seit 31.12.2021 |
|
Währung |
|
Aktienkurs |
|
Kurswert in Mio. CHF |
|
In % der Wert- schriften |
|
In % des Eigen- kapitals |
|
In % der Gesell- schaft |
|
Ionis Pharmaceuticals |
|
9 635 000 |
|
(597 973) |
|
USD |
|
37.77 |
|
336.4 |
|
11.0% |
|
12.5% |
|
6.8% |
|
Argenx SE |
|
892 503 |
|
(78 035) |
|
USD |
|
378.83 |
|
312.6 |
|
10.2% |
|
11.6% |
|
1.6% |
|
Neurocrine Biosciences |
|
2 730 000 |
|
(285 400) |
|
USD |
|
119.44 |
|
301.5 |
|
9.9% |
|
11.2% |
|
2.8% |
|
Moderna |
|
1 501 951 |
|
(161 398) |
|
USD |
|
179.62 |
|
249.4 |
|
8.2% |
|
9.3% |
|
0.4% |
|
Vertex Pharmaceuticals |
|
930 523 |
|
(99 477) |
|
USD |
|
288.78 |
|
248.4 |
|
8.1% |
|
9.2% |
|
0.4% |
|
Incyte |
|
2 891 077 |
|
(5 923) |
|
USD |
|
80.32 |
|
214.7 |
|
7.0% |
|
8.0% |
|
1.3% |
|
Alnylam Pharmaceuticals |
|
890 000 |
|
(220 000) |
|
USD |
|
237.65 |
|
195.5 |
|
6.4% |
|
7.3% |
|
0.7% |
|
Intra-Cellular Therapies |
|
3 291 479 |
|
(246 940) |
|
USD |
|
52.92 |
|
161.0 |
|
5.3% |
|
6.0% |
|
3.5% |
|
Myovant Sciences |
|
5 872 639 |
|
(249 400) |
|
USD |
|
26.96 |
|
146.4 |
|
4.8% |
|
5.5% |
|
6.1% |
|
Revolution Medicines |
|
4 777 562 |
|
1 356 100 |
|
USD |
|
23.82 |
|
105.2 |
|
3.4% |
|
3.9% |
|
5.4% |
|
Agios Pharmaceuticals |
|
4 030 792 |
|
(281 500) |
|
USD |
|
28.08 |
|
104.6 |
|
3.4% |
|
3.9% |
|
7.3% |
|
Sage Therapeutics |
|
2 950 278 |
|
(219 826) |
|
USD |
|
38.14 |
|
104.0 |
|
3.4% |
|
3.9% |
|
5.0% |
|
Celldex Therapeutics |
|
1 800 000 |
|
1 800 000 |
|
USD |
|
44.57 |
|
74.2 |
|
2.4% |
|
2.8% |
|
3.8% |
|
Arvinas |
|
2 136 412 |
|
(40 491) |
|
USD |
|
34.21 |
|
67.6 |
|
2.2% |
|
2.5% |
|
4.0% |
|
Relay Therapeutics |
|
4 120 720 |
|
34 758 |
|
USD |
|
14.94 |
|
56.9 |
|
1.9% |
|
2.1% |
|
3.4% |
|
Macrogenics |
|
8 929 963 |
|
1 654 399 |
|
USD |
|
6.71 |
|
55.4 |
|
1.8% |
|
2.1% |
|
14.5% |
|
Fate Therapeutics |
|
4 839 779 |
|
1 138 443 |
|
USD |
|
10.09 |
|
45.1 |
|
1.5% |
|
1.7% |
|
5.0% |
|
Exelixis |
|
2 654 500 |
|
(180 500) |
|
USD |
|
16.04 |
|
39.4 |
|
1.3% |
|
1.5% |
|
0.8% |
|
Crispr Therapeutics |
|
888 605 |
|
(60 979) |
|
USD |
|
40.65 |
|
33.4 |
|
1.1% |
|
1.2% |
|
1.1% |
|
Wave Life Sciences |
|
4 494 458 |
|
(108 400) |
|
USD |
|
7.00 |
|
29.1 |
|
1.0% |
|
1.1% |
|
5.2% |
|
Beam Therapeutics |
|
693 121 |
|
86 300 |
|
USD |
|
39.11 |
|
25.1 |
|
0.8% |
|
0.9% |
|
1.0% |
|
Esperion Therapeutics |
|
4 194 064 |
|
(283 900) |
|
USD |
|
6.23 |
|
24.2 |
|
0.8% |
|
0.9% |
|
5.7% |
|
Mersana Therapeutics |
|
4 066 200 |
|
(68 800) |
|
USD |
|
5.86 |
|
22.0 |
|
0.7% |
|
0.8% |
|
4.1% |
|
Kezar Life Sciences |
|
3 000 000 |
|
(1 918 148) |
|
USD |
|
7.04 |
|
19.5 |
|
0.6% |
|
0.7% |
|
4.4% |
|
Essa Pharma |
|
7 879 583 |
|
2 863 769 |
|
USD |
|
2.52 |
|
18.4 |
|
0.6% |
|
0.7% |
|
17.9% |
|
Scholar Rock Holding |
|
2 132 725 |
|
(142 400) |
|
USD |
|
9.05 |
|
17.8 |
|
0.6% |
|
0.7% |
|
4.1% |
|
Rivus Pharmaceuticals 1) |
|
|
|
|
|
USD |
|
|
|
16.2 |
|
0.5% |
|
0.6% |
|
|
|
Generation Bio Co. |
|
3 608 280 |
|
(244 900) |
|
USD |
|
3.93 |
|
13.1 |
|
0.4% |
|
0.5% |
|
6.1% |
|
Black Diamond Therapeutics |
|
5 377 839 |
|
1 937 839 |
|
USD |
|
1.80 |
|
8.9 |
|
0.3% |
|
0.3% |
|
14.8% |
|
Molecular Templates |
|
11 192 003 |
|
400 000 |
|
USD |
|
0.33 |
|
3.4 |
|
0.1% |
|
0.1% |
|
19.9% |
|
Homology Medicines |
|
1 622 522 |
|
(114 600) |
|
USD |
|
1.26 |
|
1.9 |
|
0.1% |
|
0.1% |
|
2.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Radius Health – Contingent Value Right |
|
8 733 538 |
|
8 733 538 |
|
USD |
|
0.00 |
|
0.0 |
|
0.0% |
|
0.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Wertschriften |
|
|
|
|
|
|
|
|
|
3 051.3 |
|
100.0% |
|
113.6% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Übrige Aktiven |
|
|
|
|
|
|
|
|
|
2.0 |
|
|
|
0.1% |
|
|
|
Übrige Verbindlichkeiten |
|
|
|
|
|
|
|
|
|
(367.3) |
|
|
|
(13.7%) |
|
|
|
Innerer Wert |
|
|
|
|
|
|
|
|
|
2 686.1 |
|
|
|
100.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1) Nicht börsennotierte Gesellschaft
Wechselkurs per 31.12.2022: USD/CHF: 0.9245